Evidence map›Paper›PMID 26327598›Full record

ArticleOncotarget2015

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres.

Javier A Menendez, Louisa Benboudjema, Luciano Vellon, Miguel A Rubio, Ingrid Espinoza, Judith Campisi, Ruth Lupu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Javier A MenendezProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology (ICO), Girona, Spain.
Louisa BenboudjemaEvanston Northwestern Healthcare Research Institute, Evanston, IL, USA.
Luciano VellonIBYME, CONICET-Laboratorio de Immunohematología, Buenos Aires, Argentina.
Miguel A RubioLaboratory of Hematology Service, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Ingrid EspinozaDepartment of Biochemistry, University of Mississippi, Jackson, MS, USA.
Judith CampisiLawrence Berkeley National Laboratory, Life Sciences Division, Berkeley, CA, USA.
Ruth LupuMayo Clinic, Department of Laboratory Medicine and Pathology, Division of Experimental Pathology, Rochester, MN, USA.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARHospital de Sant Pau · ESInstitut d'Investigació Biomèdica de Girona · ESLawrence Berkeley National Laboratory · USMayo Clinic in Arizona · USNorthShore University HealthSystem · USUniversity of Mississippi · US

Funding

Cyr61-induced breast cancer: Clinical relevance and therapeutic developmentR01CA118975 · NCI · NORTHSHORE UNIVERSITY HEALTHSYSTEM · PI LUPU, RUTH · 2006 to 2010
$1.5M
NCI NIH HHS R01 CA118975NCI NIH HHS R01-CA118975
6 · The paper itself

Abstract

Telomere length, shape and function depend on a complex of six core telomere-associated proteins referred to as the telosome or shelterin complex. We here demonstrate that the isoform β2 of the heregulin family of growth factors (HRGβ2) is a novel interactor of the telosome/shelterin complex in human telomeres. Analysis of protein-protein interactions using a high-throughput yeast two-hybrid (Y2H) screen identified RAP1, the only telomere protein that is conserved from yeasts to mammals, as a novel interacting partner of HRGβ2. Deletion analysis of RAP1 revealed that the linker domain, a region previously suggested to recruit negative regulators of telomere length, interacts specifically with HRGβ2. Co-immunoprecipitation and imaging experiments demonstrated that, in addition to RAP1, HRGβ2 could associate with the RAP1-associated telomeric repeat binding factor 2 (TRF2). Deletion analysis of HRGβ2 confirmed that a putative nuclear localization signal (NLS) was necessary for nuclear HRGβ2 to exert a negative regulation of telomere length whereas the N-terminus (extracellular) amino acids of HRGβ2 were sufficient to interact with RAP1/TRF2 and promote telomere shortening. Taken together, our studies identify nuclear HRGβ2 as one of the previously unknown regulators predicted to be recruited by the RAP1 linker domain to negatively regulate telomere length in human cells. Our current findings reveal that a new, but likely not the last, unexpected visitor has arrived to the "telosome/shelterin town".

Indexed as

Cell Line, TumorCell NucleusGene DeletionHumansImmunoprecipitationIn Situ Hybridization, FluorescenceMCF-7 CellsMicroscopy, FluorescenceMutationNeuregulin-1Protein BindingRNA InterferenceShelterin ComplexTelomereTelomere-Binding ProteinsTelomere Shorteningheregulin beta1Neuregulin-1Shelterin ComplexTelomere-Binding ProteinsTelomeric Repeat Binding Protein 2TERF2IP protein, humanTERF2 protein, humanheregulinshelterin complextelomeretelosomeTRF2

Identifiers

PMID26327598
PMCPMC4741835
OpenAlexW1896064826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.